Lower Alzheimer’s risk seen with PDE5i initiation for erectile dysfunction
Feb 08, 2024
The greatest reduction in risk was seen for those receiving 21 to 50 phosphodiesterase type 5 inhibitor prescriptions.
5α-reductase inhibitors linked to depression, but not dementia
Dec 29, 2022
The magnitude of association for finasteride and dutasteride with dementia decreased over time and became nonsignificant.
Gender life expectancy gap increased from 2010 to 2021
Nov 13, 2023
The leading contributors to the widening gender life expectancy gap from 2019 to 2021 included COVID-19 and unintentional injuries.
More news for Tuesday, Feb. 28
Feb 27, 2017
Sens. Collins, McCaskill urge Senate Banking Committee to consider Senior$afe Act of 2017 … Alzheimer’s drug prescribed “off-label” for mild cognitive impairment could pose risk...
Healthy lifestyle tied to longer life, delayed onset of dementia
Apr 14, 2022
Healthy lifestyle in seniors is linked to longer life expectancy and a larger proportion of remaining years spent without Alzheimer’s dementia.
Women have higher tau, especially in setting of elevated Aβ
Apr 05, 2023
Later age at menopause and hormone therapy non-use also were associated with higher regional tau.
More news for Monday, Nov. 13
By
Kimberly Bonvissuto
Nov 13, 2023
CareTrust REIT moves forward with ‘foot on the gas’ … Assisted living community pays $59K in back wages, $7K in penalties for repeat wage violations … Coalition of business groups sues...
Top 10 contributors to health loss in U.S.
By
Lois A. Bowers
Aug 31, 2015
A new analysis contains good and bad news regarding American life expectancy.
Heart disease, cancer, Alzheimer’s top list of older adult death causes
By
Lois A. Bowers
Jul 08, 2019
Heart disease, cancer and Alzheimer’s disease were the three leading causes of death for those aged 85 or more years in 2017, according to a newly released report from the Centers for Disease Control...
Allergan subsidiary settles Alzheimer’s drug lawsuit for $750 million
By
Lois A. Bowers
Oct 31, 2019
Subsidiaries of pharmaceutical company Allergan will pay $750 million to resolve a class action lawsuit from a group of direct purchasers of Alzheimer’s drug Namenda (memantine).